| Dr Tullika Garg, MD | |
|
100 North Academy Ave., Danville, PA 17822-1316 | |
| (570) 271-6328 | |
| (570) 271-6955 |
| Full Name | Dr Tullika Garg |
|---|---|
| Gender | Female |
| Speciality | Urology |
| Experience | 19 Years |
| Location | 100 North Academy Ave., Danville, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912094962 | NPI | - | NPPES |
| 102933165 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 60-225867 (New York) | Secondary |
| 208800000X | Urology | 49558020 (Wisconsin) | Secondary |
| 208800000X | Urology | MD451882 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Milton S Hershey Medical Center | Hershey, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Milton S Hershey Medical Center Physicians Group | 3870405483 | 1400 |
News Archive
Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA - a leading company in conducting early-stage discovery research programs for the life science industry - to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).
eRAD, a division of RadNet, Inc., an industry leader in workflow solutions through its native Web-based RIS, PACS and Teleradiology software platform, announced today the purchase of eRAD's integrated RIS/PACS software by Garden State Pain and Radiology Centers located in New Jersey.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.
› Verified 4 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA - a leading company in conducting early-stage discovery research programs for the life science industry - to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).
eRAD, a division of RadNet, Inc., an industry leader in workflow solutions through its native Web-based RIS, PACS and Teleradiology software platform, announced today the purchase of eRAD's integrated RIS/PACS software by Garden State Pain and Radiology Centers located in New Jersey.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.
› Verified 4 days ago
| Entity Name | The Milton S Hershey Medical Center Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710951744 PECOS PAC ID: 3870405483 Enrollment ID: O20040225000741 |
News Archive
Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA - a leading company in conducting early-stage discovery research programs for the life science industry - to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).
eRAD, a division of RadNet, Inc., an industry leader in workflow solutions through its native Web-based RIS, PACS and Teleradiology software platform, announced today the purchase of eRAD's integrated RIS/PACS software by Garden State Pain and Radiology Centers located in New Jersey.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tullika Garg, MD 100 North Academy Ave., Danville, PA 17822-4903 Ph: (570) 271-6144 | Dr Tullika Garg, MD 100 North Academy Ave., Danville, PA 17822-1316 Ph: (570) 271-6328 |
News Archive
Fast Forward, LLC, the commercial drug development arm of the National Multiple Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF), the leader in research leading to a cure for type 1 diabetes in the world today announced a collaborative partnership with Axxam SpA - a leading company in conducting early-stage discovery research programs for the life science industry - to develop new treatments for two autoimmune diseases, multiple sclerosis (MS) and type 1 diabetes (T1D).
eRAD, a division of RadNet, Inc., an industry leader in workflow solutions through its native Web-based RIS, PACS and Teleradiology software platform, announced today the purchase of eRAD's integrated RIS/PACS software by Garden State Pain and Radiology Centers located in New Jersey.
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for schizophrenia in the transgenic chakragati (ckr) model of psychosis. The mouse model screening was performed by the Contract Research Organization, Cerca Insights.
› Verified 4 days ago
Dr. Joel M. Sumfest, M.D. Urology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6328 | |
Moira E Dwyer, MD Urology Medicare: Not Enrolled in Medicare Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6328 Fax: 570-271-6578 | |
Dr. Alyssa Marie Park, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6328 Fax: 570-271-6955 | |
Dr. Brant R. Fulmer, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 100 North Academy Ave., Danville, PA 17822 Phone: 570-271-6328 Fax: 570-271-6955 | |
Dr. Heinric Williams, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6328 Fax: 570-271-6955 | |
Dr. Robert Eric Steckler, M.D. Urology Medicare: Medicare Enrolled Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6328 | |
Dr. Ryan Lee Mori, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 100 N Academy Ave, Danville, PA 17822 Phone: 570-271-6328 Fax: 570-271-6955 |